https://www.selleckchem.com/products/loxo-292.html
857). In addition, the 3-year cumulative nonrecurrence rate in the high-risk group stratified by this model was 21.8% compared to 98.1% in the low-risk group. This study proposed a new nomogram including tumor differentiation and mutation to predict recurrence or metastatic probability in stage IA LADC patients who underwent radical surgery. This nomogram could identify patients in the high-risk group and help guide adjuvant treatment in the future. This study proposed a new nomogram including tumor differentiation and EGFR mutation to
Like
Comment
Share
